Solas Capital Management LLC lessened its holdings in ZimVie Inc. (NASDAQ:ZIMV - Free Report) by 12.6% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 340,536 shares of the company's stock after selling 49,220 shares during the period. ZimVie comprises 2.1% of Solas Capital Management LLC's holdings, making the stock its 15th biggest position. Solas Capital Management LLC owned 1.22% of ZimVie worth $3,678,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. AlphaQuest LLC lifted its holdings in ZimVie by 2,695.9% during the first quarter. AlphaQuest LLC now owns 8,947 shares of the company's stock worth $97,000 after buying an additional 8,627 shares during the period. Quantbot Technologies LP purchased a new stake in ZimVie during the first quarter worth $98,000. Hsbc Holdings PLC purchased a new stake in shares of ZimVie during the 1st quarter worth $144,000. State of Wyoming lifted its stake in shares of ZimVie by 132.2% during the 1st quarter. State of Wyoming now owns 16,318 shares of the company's stock worth $176,000 after purchasing an additional 9,291 shares during the last quarter. Finally, Wealthquest Corp purchased a new stake in shares of ZimVie during the 1st quarter worth $182,000. Hedge funds and other institutional investors own 95.63% of the company's stock.
ZimVie Stock Performance
Shares of NASDAQ:ZIMV traded up $0.06 during trading on Tuesday, hitting $18.94. The stock had a trading volume of 1,059,082 shares, compared to its average volume of 314,657. ZimVie Inc. has a 12-month low of $8.15 and a 12-month high of $19.01. The stock has a market capitalization of $534.11 million, a price-to-earnings ratio of -27.06 and a beta of 2.19. The company has a quick ratio of 1.60, a current ratio of 2.37 and a debt-to-equity ratio of 0.56. The stock has a 50-day simple moving average of $15.42 and a two-hundred day simple moving average of $12.02.
ZimVie (NASDAQ:ZIMV - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.05. ZimVie had a positive return on equity of 6.37% and a negative net margin of 4.39%.The firm had revenue of $116.66 million during the quarter, compared to analysts' expectations of $112.60 million. On average, equities research analysts expect that ZimVie Inc. will post 0.6 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have commented on ZIMV. UBS Group decreased their price target on shares of ZimVie from $16.00 to $10.00 and set a "neutral" rating for the company in a research report on Thursday, May 15th. Wall Street Zen lowered shares of ZimVie from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. B. Riley cut shares of ZimVie from a "buy" rating to a "neutral" rating and set a $19.00 target price for the company. in a research report on Thursday, July 31st. Finally, Barclays raised shares of ZimVie from an "underweight" rating to an "equal weight" rating and increased their target price for the company from $9.00 to $19.00 in a research report on Tuesday, July 22nd. Four analysts have rated the stock with a Hold rating, Based on data from MarketBeat, ZimVie has a consensus rating of "Hold" and an average price target of $17.75.
Get Our Latest Stock Report on ZIMV
ZimVie Profile
(
Free Report)
ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.
Further Reading
Before you consider ZimVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ZimVie wasn't on the list.
While ZimVie currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
